- DKK29.44bn
- DKK29.79bn
- DKK4.78bn
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 57.96 | ||
| PEG Ratio (f) | 1.45 | ||
| EPS Growth (f) | 66.44% | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 5.43 | ||
| Price to Tang. Book | 15.9 | ||
| Price to Free Cashflow | 58.76 | ||
| Price to Sales | 6.01 | ||
| EV to EBITDA | 42.08 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 5.88% | ||
| Return on Equity | 4.99% | ||
| Operating Margin | 7.19% | ||
Financial Summary
| Year End 30th Sep | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | DKKm | 2,820 | 3,567 | 4,013 | 4,444 | 4,775 | 5,266.38 | 5,933.52 | 12.88% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | +34.45 | -45.52 | -0.17 | +18.27 | -38.53 | +101.02 | +53.74 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Ambu A/S is a Denmark-based company engaged in the development, manufacture and marketing of diagnostic and life-supporting devices for hospitals and rescue services. The Company’s operations are structured into three business areas: Anaesthesia, Patient Monitoring & Diagnostics and Emergency Care. The Anaesthesia business area offers a range of products such as resuscitators, face masks and laryngeal masks. The Patient Monitoring & Diagnostics business area comprises single use electrodes for cardiological and neurological examinations. The target groups for these products are hospitals, clinics, ambulance services and sleep labs. The Emergency Care business area offers ventilation bags, neck collars and manikins for first-aid training. The Company markets its products worldwide. The Company operates King Systems Inc, First Water Heathcote Ltd and Invendo Medical GmbH as subsidiaries.
Directors
- Jorgen Jensen NEC (53)
- Juan-Jose Gonzalez CEO (48)
- Christian Sagild NVC (62)
- Michael Hoejgaard CFO (56)
- Jakob Boennelykke Kristensen DRC (48)
- Jakob Koch DRC (41)
- Thomas Lykke Henriksen DRC (47)
- Britt Meelby Jensen IND (47)
- Henrik Wulff IND (50)
- Last Annual
- September 30th, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- December 3rd, 1956
- Public Since
- March 9th, 1992
- No. of Shareholders
- 68,944
- No. of Employees
- 4,700
- Sector
- Healthcare Equipment & Supplies
- Industry
- Healthcare
- Exchange
OMX Nordic Exchange - Copenhagen- Shares in Issue
- 266,301,620
- Address
- Baltorpbakken 13, BALLERUP, 2750
- Web
- https://www.ambu.com/
- Phone
- +45 72252000
- Contact
- Anders Hjort
- Auditors
- EY Godkendt Revisionspartnerselskab
Upcoming Events for AMBU B
Q3 2024 Ambu A/S Earnings Release
Similar to AMBU B
Bactiquant A/S
OMX Nordic Exchange - Copenhagen
BioPorto A/S
OMX Nordic Exchange - Copenhagen
ChemoMetec A/S
OMX Nordic Exchange - Copenhagen
Coloplast A/S
OMX Nordic Exchange - Copenhagen
Demant A/S
OMX Nordic Exchange - Copenhagen
FAQ
What is the Ambu A/S share price?
As of Today at 01:02 UTC, shares in Ambu A/S are trading at DKK110.55. This share price information is delayed by 15 minutes.
How has the Ambu A/S share price performed this year?
Shares in Ambu A/S last closed at DKK110.55 and the price had moved by +1.52% over the past 365 days. In terms of relative price strength the Ambu A/S share price has underperformed the FTSE Global All Cap Index by -7% over the past year.
What are the analyst and broker recommendations for Ambu A/S?
The overall consensus recommendation for Ambu A/S is Hold. You can view the full broker recommendation list by unlocking its StockReport.
What is the Ambu A/S dividend yield?
Ambu A/S does not currently pay a dividend.
Does Ambu A/S pay a dividend?
Ambu A/S does not currently pay a dividend.
When does Ambu A/S next pay dividends?
Ambu A/S does not currently pay a dividend.
How do I buy Ambu A/S shares?
To buy shares in Ambu A/S you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Ambu A/S?
As of the previous close price of DKK110.55, shares in Ambu A/S had a market capitalisation of DKK29.44bn.
Where are Ambu A/S shares listed?
Here are the trading details for Ambu A/S:
- Country of listing: Denmark
- Exchange: CPH
- Ticker Symbol: AMBU B
What kind of share is Ambu A/S?
Based on an overall assessment of its quality, value and momentum Ambu A/S is currently classified as a High Flyer. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Ambu A/S share price forecast for 2024?
The analyst consensus target price for shares in Ambu A/S is DKK121.80. That is 10.18% above the last closing price of DKK110.55.
Analysts covering Ambu A/S currently have a consensus Earnings Per Share (EPS) forecast of DKK1.46 for the next financial year.
What is the trend in the Ambu A/S share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Ambu A/S. Over the past six months, its share price has outperformed the FTSE Global All Cap Index by +38.99%.
As of the last closing price of DKK110.55, shares in Ambu A/S were trading +13.4% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Ambu A/S PE Ratio?
The Ambu A/S PE ratio based on its reported earnings over the past 12 months is 57.96. The shares last closed at DKK110.55.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Ambu A/S?
Ambu A/S' management team is headed by:
- Jorgen Jensen - NEC
- Juan-Jose Gonzalez - CEO
- Christian Sagild - NVC
- Michael Hoejgaard - CFO
- Jakob Boennelykke Kristensen - DRC
- Jakob Koch - DRC
- Thomas Lykke Henriksen - DRC
- Britt Meelby Jensen - IND
- Henrik Wulff - IND